Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
What is known and objective Both metformin and acarbose are recommended monotherapy and add-on therapy in type 2 diabetes mellitus ( T2 DM). A fixed-dose combination ( FDC) of acarbose and metformin has been developed to reduce pill burden and potentially improve compliance. The current study invest...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 39; no. 4; pp. 424 - 432 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |